Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9720156 | 0.87 | GAA (0.50) | GAAALDH1A1TSHRCYP2D6CYP2C9 | |
| SCHEMBL13827068 | 0.82 | GAA (0.42) | GAAALDH1A1TSHR | |
| SCHEMBL17356885 | 0.79 | GAA (0.44) | GAAALDH1A1TSHRCYP2D6CYP2C9 | |
| SCHEMBL607878 | 0.78 | DGAT1 (0.31) | GAAALDH1A1TSHR | |
| SCHEMBL13003089 | 0.77 | GAA (0.42) | GAAALDH1A1TSHR | |
| SCHEMBL13434035 | 0.77 | GAA (0.42) | GAAALDH1A1TSHR | |
| SCHEMBL18156057 | 0.77 | GAA (0.42) | GAAALDH1A1TSHR | |
| SCHEMBL607879 | 0.75 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL15398133 | 0.75 | GAA (0.46) | GAAALDH1A1TSHRCYP2D6CYP2C9 | |
| SCHEMBL10593835 | 0.75 | GAA (0.41) | GAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11762287-B2 | Onium salt compound, chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-19 | — | — | US | disclosed |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-03-09 | — | — | US | disclosed |
| US-20150368394-A1 | CATALYSTS AND METHODS FOR POLYESTER PRODUCTION | NOVOMER, INC. | 2015-12-24 | — | — | US | disclosed |
| US-8445476-B2 | Carbacephem β-lactam antibiotics | ACHAOGEN, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445476-B2 | Carbacephem β-lactam antibiotics | ACHAOGEN, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7291612-B2 | Immunomodulatory compounds | ACTIVE BIOTECH A.B. (SE) | 2007-11-06 | — | — | US | disclosed |
| US-20070238736-A9 | INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME | SIRCAR JAGADISH | 2007-10-11 | — | — | US | disclosed |
| US-20070194305-A1 | Organic thin film transistor comprising fluorine-based polymer thin film and method for fabricating the same | SAMSUNG ELECTRONICS CO., LTD. | 2007-08-23 | — | — | US | disclosed |
| US-20070179132-A1 | INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-7235546-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054923-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-03-08 | — | — | US | disclosed |
| US-20070054920-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-03-08 | — | — | US | disclosed |
| US-20070054898-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-03-08 | — | — | US | disclosed |
| US-20070054922-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-03-08 | — | — | US | disclosed |
| US-7173036-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224186-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | GAA 2536/4885ALDH1A1 2455/4885TSHR 3315/4885 |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | GLP1R, GIPR, FXR1 | GAA 807/4885ALDH1A1 3231/4885TSHR 237/4885 |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | GAA 733/4885ALDH1A1 1412/4885TSHR 600/4885 |
| US-20070179132-A1 | INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME | MIF, MSR1, MMP12 | GAA 2209/4885ALDH1A1 1799/4885TSHR 2132/4885 |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | GAA 2452/4885ALDH1A1 2468/4885TSHR 2986/4885 |
| US-11762287-B2 | Onium salt compound, chemically amplified resist composition and patterning process | IDUA, SLC6A5, SLC6A9 | GAA 740/4885ALDH1A1 4322/4885TSHR 3502/4885 |
| US-20070238736-A9 | INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME | MIF, MSR1, MMP12 | GAA 2209/4885ALDH1A1 1799/4885TSHR 2132/4885 |
| US-20070054898-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | MIF, MSR1, MMP12 | GAA 2209/4885ALDH1A1 1799/4885TSHR 2132/4885 |
| US-20070054920-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | MIF, MSR1, MMP12 | GAA 2209/4885ALDH1A1 1799/4885TSHR 2132/4885 |
| US-20070054923-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | MIF, MSR1, MMP12 | GAA 2209/4885ALDH1A1 1799/4885TSHR 2132/4885 |
| US-20070054922-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | MIF, MSR1, MMP12 | GAA 2209/4885ALDH1A1 1799/4885TSHR 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.